Share on StockTwits
 

Eli Lilly & Co. (NYSE:LLY) is scheduled to release its earnings data on Thursday, January 30th. Persons interested in participating in the company’s earnings conference call can do so using this link.

Eli Lilly & Co. (NYSE:LLY) opened at 54.23 on Wednesday. Eli Lilly & Co. has a 52-week low of $47.53 and a 52-week high of $58.40. The stock’s 50-day moving average is $51.83 and its 200-day moving average is $51.48. The company has a market cap of $58.579 billion and a P/E ratio of 12.39.

The company also recently declared a quarterly dividend, which is scheduled for Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of 0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.61%. The ex-dividend date of this dividend is Wednesday, February 12th.

Several analysts have recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Eli Lilly & Co. from a “neutral” rating to a “buy” rating in a research note to investors on Monday, January 13th. On a related note, analysts at Barclays downgraded shares of Eli Lilly & Co. from an “equal weight” rating to an “underweight” rating in a research note to investors on Friday, January 10th. They now have a $51.00 price target on the stock, down previously from $58.00. Finally, analysts at BMO Capital Markets downgraded shares of Eli Lilly & Co. from a “market perform” rating to an “underperform” rating in a research note to investors on Wednesday, January 8th. They now have a $50.00 price target on the stock. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the stock. Eli Lilly & Co. presently has a consensus rating of “Hold” and a consensus price target of $54.33.

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.